All In Biotech

Drug Trial Radar · NCT06887803

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to an Approved JAK Inhibitors (HEMA-MED)

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

26

Planned (sponsor's estimate)

Start

Nov 17, 2025

Primary completion

Mar 2028

Study completion Jul 2028

Sponsor

Lead sponsor
iOncturaIndustry
Sponsor type
Industry
First posted
Mar 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with Myelofibrosis. The main questions it aims to answer is to evaluate the safety and tolerability of roginolisib when administered in combination with ruxolitinib.

Conditions

  • Myelofibrosis (MF)

Interventions

  • RoginolisibDrug

    IOA-244: 80 mg (corresponding to 72 mg roginolisib) Ruxolitinib: up to 25 mg BD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment emergent adverse eventsTime frame: Day 1 and 15 of cycle 1; Day 1 of each subsequent cycle whilst on treatment anticipated to be 52 weeks. Cycle length 28 days
  2. Number of Participants with abnormal ECG recordingsTime frame: Day 1 of each cycle whilst on treatment anticipated to be 52 weeks. Cycle length 28 days
  3. Number of participants with abnormal laboratory parametersTime frame: Day 1 and 15 of cycle 1; Day 1 of each subsequent cycle whilst on treatment anticipated to be 52 weeks. Cycle length 28 days
  4. Number of participants with changes in blood pressure measurementsTime frame: Day 1 and 15 of cycle 1; Day 1 of each subsequent cycle whilst on treatment anticipated to be 52 weeks. Cycle length 28 days

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Istituto di Ematolgia e Oncologia Medica

    Bologna, Italy · Recruiting

  • Istituto Romagnolo per lo Studio dei Tumori

    Meldola, Italy · Recruiting

  • Azienda Sanitario Universitaria Friuli Centrale

    Udine, Italy · Recruiting

  • Azienda Ospedaliero Universitaria Careggi Firenze, Struttura Complessa di Ematologia

    Florence, Florence, Italy · Recruiting

  • IRCCS Clinical Institute Humanitas

    Rozzano, Milan, Italy · Recruiting

  • Vall d'Hebron University Hospital

    Barcelona, Spain · Recruiting

  • Avigunda Gran via de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat

    Barcelona, Spain · Recruiting

  • START Madrid CIOCC

    Madrid, Spain · Recruiting

  • Hospital Universitario de Salamanca

    Salamanca, Spain · Recruiting

  • Belfast City Hospital

    Belfast, United Kingdom · Recruiting

  • Guy´s and St. Thomas NHS Foundation Trust

    London, United Kingdom · Not yet recruiting

  • United Lincolnshire Teach Hospitals NHS Trust, Pilgrim Hospital Boston

    Boston, Lincolnshire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.